EMG
CERE

ETF Managers Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

ETF Managers Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,313
Closed -$357K – 751
2022
Q4 		$357K Buy
+11,313
New +$319K 0.02% 409

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ETF Managers Group's CERE Position: Q1 2023 in Review

ETF Managers Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2023, closing a stake of 11,313 shares — an estimated $357K sold.

ETF Managers Group first reported a position in CERE in Q4 2022 and held it in 1 quarter. The position peaked at $357K in Q4 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q1 2023.

  • ETF Managers Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • ETF Managers Group sold 11,313 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2023, an estimated $357K.
  • ETF Managers Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • ETF Managers Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $357K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.